- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Sailaja Darisipudi | Authors
Elacestrant Bests Standard of Care in PFS in ER Positive/HER2-Negative Metastatic Breast Cancer
December 08, 2022
Patients with ER-positive/HER2-negative metastatic breast cancer had improved progression-free survival when treated with elacestrant compared with standard of endocrine therapy.
Trastuzumab Deruxtecan Improves Survival in HER-2 Positive Breast Cancer Compared to Capecitabine Regimens
December 07, 2022
Patients with advanced HER2-positive breast cancer had improved progression-free and overall survival when treated with trastuzumab deruxtecan compared with capecitabin-based treatment, according to recent findings.
Advertisement
Advertisement